Medpace Holdings (Nasdaq: MEDP) – provides clinical development services to biotech, pharmaceutical, and medical device companies. The company is headquartered in Cincinnati, Ohio and was founded in 1992.
They don’t develop drugs and devices, but rather they offer a suite of services to the developers that can support the products throughout the trial process, from Phase I to Phase IV.
Sales have increased at a rate of 24% per year over the last three years and they were up 23% in the first quarter.
The company also boasts strong management efficiency measurements with a return on equity of 17.5% and a profit margin of 17.5%.
The sentiment is really interesting for Medpace as there are only three analysts following the stock.
All three have the stock rated as a “buy”, but the fact that a company with a $2 billion market cap and that trades 500K shares a day only has three analysts following it is surprising. Rather than having bearish sentiment from analysts, it is flying below their radar.
The short interest ratio on Medpace is currently at 4.4. The ratio has doubled since the end of February when it was only 2.2.
The weekly chart shows how the stock has been moving higher within a trend channel over the last year and a half. Like most healthcare stocks, Medpace has slipped in the last few months. The stock appears to be finding support at the lower rail of the channel and the 52-week moving average. I look for the stock to resume its upward trend in the coming months.
Suggested strategy: Buy MEDP with a maximum entry price of $57.00. I would set a target of at least $75 over the next 9 to 12 months. I would also suggest a stop at $50.00.
— Rick PendergraftAvoid These 5G Stocks Like the Plague [sponsor]
The 5G communication build-out is going to be the biggest, most important, most lucrative new “highway” built in our lifetimes. Yet most people are investing in it the WRONG way. Legendary stock picker Matt McCall reveals details about the best 5G stocks to buy now. Click here to learn more.